By Denny Jacob
Humacyte shares surged 38% in premarket trading a day after disclosing the Food and Drug Administration granted full approval of Symvess for adults.
Shares were trading around $4.81. The stock is up 22% on the year.
The biotechnology company said the approval applies to use of the treatment as a vascular conduit for extremity arterial injury when blood flow needs to urgently be restored to avoid imminent limb loss, and when a graft of a vein used to repair blood vessels isn't feasible.
Symvess was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds and industrial accidents, said Humacyte.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 20, 2024 06:56 ET (11:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。